Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urivent
- Development stage
- Unknown
- Lead developer
- Al-Madina Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Urivent is an approved generic formulation of tamsulosin hydrochloride developed and manufactured by Al-Madina Pharmaceuticals. It is a selective alpha-1 adrenergic receptor antagonist, specifically targeting the alpha-1A and alpha-1D receptor subtypes. These receptors are predominantly located in the smooth muscle of the human prostate, prostatic urethra, and bladder neck. By blocking these receptors, Urivent relaxes the smooth muscle tissue, which reduces urethral resistance, improves urine flow rate, and alleviates lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
- Brand names
- Urivent
- Other names
- tamsulosintamsulosin HCltamsulosin hydrochloride
02
Targets
ADRA1A (α1A)ADRA1D (α1D)
Beyond the preview
Go deeper on Urivent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Urivent.